

**Engelberg Global Fund IC Limited**

**Annual Report and Audited Financial Statements for the period  
from 19 March 2019 to 30 June 2020**

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

<b>Contents</b>	<b>Page</b>
General Information	3
Investment Manager's Report	4
Directors' Report	5
Independent Auditor's Report	6
Custodian's Report	8
Supplementary Information	9
Portfolio Statement	10
Statement of Financial Position	11
Statement of Comprehensive Income	12
Statement of Cash Flows	13
Statement of Changes in Net Assets attributable to Holders of Participating Redeemable Shares	14
Notes to the Financial Statements	15

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**General Information**

**Address and Registered Office**

PO Box 255  
Trafalgar Court, Les Banques  
St Peter Port, Guernsey  
Channel Islands, GY1 3QL

**Investment Manager**

Momentum Global Investment Management Limited  
The Rex Building  
62 Queen Street  
London  
EC4R 1EB  
United Kingdom

**Distribution Partner**

Engelberg (Pty) Ltd  
Ground Floor Block 1  
Waterfront Terraces  
Carl Cronje Drive  
Tygerwaterfront  
Bellville  
Western Cape  
7530, South Africa

**Manager**

Momentum Wealth International Limited  
La Plaiderie House  
La Plaiderie  
St Peter Port, Guernsey  
Channel Islands  
GY1 1WF

**Custodian**

Northern Trust (Guernsey) Limited  
PO Box 71  
Trafalgar Court  
Les Banques  
St Peter Port, Guernsey  
Channel Islands  
GY1 3DA

**Directors of the Incorporated Cell**

Robert Alastair Rhodes  
Roxanne Power  
Marie Curutchet  
Ferdinand van Heerden (effective from 1 September 2019)

**Administrator, Registrar & Secretary**

Northern Trust International Fund Administration  
Services (Guernsey) Limited  
PO Box 255  
Trafalgar Court  
Les Banques  
St Peter Port, Guernsey  
Channel Islands  
GY1 3QL

**Legal Advisors**

Carey Olsen  
Carey House  
Les Banques  
St Peter Port, Guernsey  
Channel Islands  
GY1 4BZ

**Independent Auditor**

Ernst & Young LLP  
PO Box 9  
Royal Chambers  
St Julian's Avenue  
St Peter Port, Guernsey  
Channel Islands  
GY1 4AF

## **Engelberg Global Fund IC Limited**

### **Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

#### **Investment Manager's Report**

The Engelberg Global Fund rebounded in the second quarter as risk assets rallied across the board. Within our equity allocation the standout performers were growth orientated strategies with greater exposure to technology, communications, healthcare and certain consumer areas. Jennison and Granahan epitomised this with impressive returns both year to date and over Q2. While global value indices generally lagged the market over the period, our discretionary managers delivered some pleasing excess returns to recover some of their losses from earlier in the year.

The latent value mentioned last quarter has also started to emerge across other asset classes too. Within fixed income, we saw strong returns coming through emerging market debt, global credit and infrastructure-related loans, all of which outperformed government bonds handsomely. Investing higher up the capital structure compared to common equity gives us some more protection if the economic damage from the virus proves to be worse than expected, while still offering the potential for attractive returns. Current yields are still pricing for overly pessimistic default rates in our view and we have already profited from prices pulling towards par over the past quarter.

Global property also partially recovered from the shock last quarter as the impact of support packages has become felt, while our position in gold returned close to 10% as the asset has become a more attractive hedge as central bank policy has reduced government bond yields across the globe.

The Engelberg Global Fund was launched in August 2019. The Fund's allocation to gold has contributed positively to performance since that time. The key detractors have been manager selection within equity and, to a lesser extent, the inclusion of regional satellites which bias the Fund in favour of world ex US equities. On the former, we retain a balance of equity investment styles within the Fund but the good relative performance of our quality and growth managers has not been sufficient to offset the underperformance of our value managers during this period. This outcome should be viewed in the context of the worst drawdown for value relative to growth since data is available on Bloomberg, beginning in 1974; much more significant than during the dotcom bubble at the start of the millennium. With respect to the regional tilts within the Fund, US equities have enjoyed an unbroken run of outperformance since the financial crisis, resulting in the biggest outperformance of world ex US equities since data is available on Bloomberg. This seemingly ignores the world class businesses that are listed outside of the US.

Equity markets have rebounded sharply and there are reasons for caution at this juncture: the US is struggling to contain a second wave of the virus and hence plans to ease restrictions are either being delayed or reversed. Meanwhile income support schemes for people who have lost their jobs or been furloughed are coming to an end, at which point the true impact of record high unemployment figures will be felt by economies. Against this backdrop, the valuations of certain companies and sectors within equity markets look challenging: Tesla is now the world's largest car manufacturer on the basis of its share price, ahead of Toyota despite selling 10 million fewer cars in 2019.

As we enter another earnings season, we are likely to see corporates reporting some large losses as the full extent of economic shutdowns are laid bare. Analyst expectations are already factoring in ~45% declines however, so much of this is already in the price and the focus will be on business solvency and how companies are adapting to the new normal. Our managers remain invested in well run businesses, some of which are likely to entrench their competitive advantages throughout this crisis, however we remain mindful of developing macro risks around the US and elsewhere. We will continue to monitor these developments closely while running a well diversified and resilient portfolio to withstand any future unexpected shocks.

# Engelberg Global Fund IC Limited

## Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020

### Directors' Report

The Directors present their annual report together with the audited financial statements of Engelberg Global Fund IC Limited (the "Incorporated Cell" or "Cell") for the period ended 30 June 2020.

#### Principal activities

The Cell with company number 66191 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company").

#### COVID-19 assessment

The Directors have, at the time of approving the financial statements, assessed the potential impact of the COVID-19 global pandemic on the Cell. Refer to note 2 for the detailed disclosure.

#### Directors

The Directors of the Cell during the period and at the date of this report are set out on page 3.

#### Directors' interests

None of the Directors who held office during the period and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

#### Directors' responsibilities

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss of the Incorporated Cell for that period. In preparing these financial statements the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 1987. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell has complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission, to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.

The annual report together with the audited financial statements of the Incorporated Cell is published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

#### Independent auditors

In June 2017, the Independent Regulatory Board of Auditors published a rule prescribing that auditors of public interest entities in South Africa must comply with mandatory audit firm rotation ("MAFR"), whereby audit firms shall not serve as the appointed auditor of a public interest entity for more than 10 consecutive years, with effect from 1 April 2023.

On 9 December 2019, Ernst & Young LLP, was appointed as Auditor to the Incorporated Cell in accordance with Article 31.1 of the Cell's Articles of Incorporation and section 258 of the Companies (Guernsey) Law, 2008.

**Marie Curutchet**  
Director  
18 December 2020



**Robert Rhodes**  
Director



# **Engelberg Global Fund IC Limited**

## **Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

### **Independent Auditor's Report to the Members of Engelberg Global Fund IC Limited**

#### **Opinion**

We have audited the financial statements of Engelberg Global Fund IC Limited (the "Incorporated Cell") for the period ended 30 June 2020 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, and the related notes 1 to 17, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2020 and of the Incorporated Cell's profit for the period then ended;
- have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of the Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey) Law, 1987.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report below. We are independent of the Incorporated Cell in accordance with the ethical requirements issued by the International Ethics Standards Board for Accountants that are relevant to our audit of the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Conclusions relating to going concern**

We have nothing to report in respect of the following matters in relation to which the ISAs require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Incorporated Cell's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

#### **Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

#### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters in relation to which the Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Incorporated Cell; or
- the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

#### **Responsibilities of directors**

As explained more fully in the directors' responsibilities statement set out on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

## **Engelberg Global Fund IC Limited Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

### **Independent Auditor's Report to the Members of Engelberg Global Fund IC Limited (continued)**

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but, is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Incorporated Cell's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Incorporated Cell's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Incorporated Cell to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### **Use of our report**

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of the Companies (Guernsey) Law, 2008. Our audit work has been undertaken so that we might state to the Incorporated Cell's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.



Ernst & Young LLP  
Guernsey, Channel Islands

 December 2020

#### **Notes:**

1. The maintenance and integrity of the Momentum Mutual Fund ICC Limited web site is the responsibility of the directors; the work carried out by the auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may have occurred to the financial statements since they were initially presented on the web site.
2. Legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**  
**Custodian's Report to the Members of Engelberg Global Fund IC Limited**

In our opinion, the Cell has, in all material aspects, been managed for the period 01 July 2019 to 30 June 2020 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules 2013.



**For and on behalf of**  
**Northern Trust (Guernsey) Limited**  
18 December 2020

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Supplementary Information**

	<b>30.06.20</b>
<b>1. NUMBER OF SHARES OUTSTANDING</b>	
Class A	23,513,824
<b>2. NET ASSET VALUE PER SHARE - USD</b>	
Class A	1.01
<b>3. HIGHEST/LOWEST PRICE - USD*</b>	
Class A	1.06 / 0.86
<b>4. NUMBER OF SHARES SUBSCRIBED</b>	
Class A	24,957,237
<b>5. NUMBER OF SHARES REDEEMED</b>	
Class A	1,443,413

\*The highest/lowest price is based on prices from the date of incorporation, 19.03.2019, to the current period end, being the 30.06.2020. The NAV on the 30.06.2020 was specifically calculated for financial reporting purposes and therefore may differ slightly from the most recent published price at that time.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Portfolio Statement**

	Holdings	Fair Value USD	% of Net Assets
<b>Financial assets at fair value through profit or loss</b>			
<b>Government Bonds 13.33%</b>			
United States Treasury Inflation Indexed Bonds 0.625% 15/02/2043	552,700	725,592	3.05
United States Treasury Note/Bond 2.125% 31/05/2026	460,000	506,647	2.13
United States Treasury Note/Bond 2.875% 15/11/2021	1,870,000	1,939,321	8.15
<b>Total Government Bonds</b>		<b>3,171,560</b>	<b>13.33</b>
<b>Collective Investment Schemes 85.78%</b>			
<b>Commodity Funds</b>			
iShares Physical Gold ETF	69,635	2,429,217	10.21
<b>Total Commodity Funds</b>		<b>2,429,217</b>	<b>10.21</b>
<b>Equity Funds</b>			
Fidelity Funds - Emerging Markets Fund	27,961	392,578	1.65
iShares Developed Real Estate Index Fund	100,165	1,074,673	4.52
Maple-Brown Abbott Global Fund	1,009,802	1,239,835	5.21
Momentum MGF Global Equity Fund Class M	32,087	4,112,207	17.28
Sands Capital Funds - Sands Emerging Markets Growth Fund	24,134	373,351	1.57
<b>Total Equity Funds</b>		<b>7,192,644</b>	<b>30.23</b>
<b>Fixed Income Funds</b>			
AXA IM Fixed Income Investment Strategies - US Short Duration High Yield	3,392	684,944	2.88
Institutional Cash Series - Institutional US Dollar Ultra Short Bond Fund	40,139	4,355,223	18.31
iShares JP Morgan \$ Emerging Markets Bond UCITS ETF	7,657	830,172	3.49
Jupiter Global Emerging Markets Short Duration Bond	12,244	1,353,606	5.69
Muzinich Funds - Enhanced Yield Short-Term Fund	7,483	1,386,533	5.83
<b>Total Fixed Income Funds</b>		<b>8,610,478</b>	<b>36.20</b>
<b>Investment Trusts</b>			
Sequoia Economic Infrastructure Income Fund	741,299	952,587	4.00
<b>Total Investment Trusts</b>		<b>952,587</b>	<b>4.00</b>
<b>Property Funds</b>			
Third Avenue Real Estate Value Fund	37,769	1,221,682	5.14
<b>Total Property Funds</b>		<b>1,221,682</b>	<b>5.14</b>
<b>Total Collective Investment Schemes</b>		<b>20,406,608</b>	<b>85.78</b>
<b>Financial assets at fair value through profit or loss</b>		<b>23,578,168</b>	<b>99.11</b>
<b>Other Net Assets 0.89%</b>		<b>212,852</b>	<b>0.89</b>
<b>Net Assets Attributable to Holders of Participating Redeemable Shares</b>		<b>23,791,020</b>	<b>100.00</b>

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Statement of Financial Position**

	Notes	Period ended 30.06.20 <u>USD</u>
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Financial assets at fair value through profit or loss	6	23,578,168
Cash and cash equivalents	7	351,922
Interest receivable	8	9,135
Other receivables	8	4,087
<b>Total assets</b>		<u>23,943,312</u>
<b>LIABILITIES</b>		
<b>CURRENT LIABILITIES</b>		
Bank overdraft		
Other payables	10	37,681
Fair value of derivative financial instruments	9	2,711
Due on redemption of participating redeemable shares		111,800
participating redeemable shares)		152,192
Net assets attributable to holders of participating redeemable shares	3 & 12	23,791,020
<b>Total liabilities</b>		<u>23,943,212</u>
<b>SHAREHOLDERS' EQUITY</b>		
Management shares	11	100
<b>Total equity</b>		<u>100</u>
<b>Total equity and liabilities</b>		<u>23,943,312</u>
Net asset value per participating redeemable share		
Class A	12	1.01


The notes 1 to 17 on pages 15 to 25 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 18 December 2020 and signed on its behalf by:

Marie Curutchet  
Director



Robert Rhodes  
Director



**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**  
**Statement of Comprehensive Income**

		For the period from 19.03.19 (date of incorporation) to 30.06.20
	Notes	<u>USD</u>
<b>INCOME</b>		
Net realised losses on financial assets at fair value through profit or loss	6	(88,308)
Net unrealised gains on financial assets at fair value through profit or loss	6	404,205
Net gain on financial assets at fair value through profit or loss		<u>315,897</u>
Deposit interest		1,157
Bond interest		47,743
Dividend income		49,804
Net gains on forward derivative contracts		7,438
Other foreign exchange losses		(8,163)
<b>Total net income</b>		<u><b>413,876</b></u>
<b>EXPENSES</b>		
Audit fee		(6,973)
Custodian fee	14	(9,166)
Investment Management fee	14	(45,764)
Management and Administration fee	14	(161,040)
Sundry expenses		(4,666)
<b>Total operating expenses</b>		<u><b>(227,609)</b></u>
<b>Net profit for the period</b>		<u><b>186,267</b></u>
<b>Increase in net assets attributable to holders of participating redeemable shares from operations</b>		<u><u><b>186,267</b></u></u>

All items in the above statement derive from continuing operations. There is no difference between the increase in net assets attributable to holders of participating redeemable shares and comprehensive income.

The notes 1 to 17 on pages 15 to 25 form part of these financial statements.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**  
**Statement of Cash flows**

	For the period from 19.03.19 (date of incorporation) to 30.06.20 <u>USD</u>
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>	
Increase in net assets attributable to holders of participating redeemable shares from operations	186,267
<b>ADJUSTMENT FOR:</b>	
Net realised loss on financial assets at fair value through profit or loss	88,308
Net unrealised gains on financial assets at fair value through profit or loss	(404,205)
Net settlement on derivatives and other foreign exchange	10,874
Dividend income	(49,804)
Interest income	(47,743)
<b>Operating loss before working capital changes</b>	<b><u>(216,303)</u></b>
Net increase in other receivables	(3,987)
Net increase in other payables	37,681
Purchase of financial assets at fair value through profit or loss	(40,044,927)
Sale of financial assets at fair value through profit or loss	16,782,656
Dividends received	49,804
Interest received	38,608
<b>Net cash used in operating activities</b>	<b><u>(23,356,468)</u></b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>	
Cash received from issuance of participating redeemable shares	25,079,127
Cash paid on redemption of participating redeemable shares	(1,362,574)
<b>Net cash generated from financing activities</b>	<b><u>23,716,553</u></b>
<b>Net increase in cash and cash equivalents</b>	<b>360,085</b>
<b>Cash and cash equivalents at the date of incorporation</b>	<b>-</b>
Net settlement on derivatives and other foreign exchange	(8,163)
<b>Cash and cash equivalents at the end of the period</b>	<b><u><u>351,922</u></u></b>

The notes 1 to 17 on pages 15 to 25 form part of these financial statements.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**  
**Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares**

	Notes	For the period from 19.03.19 (date of incorporation) to 30.06.20 <u>USD</u>
<b>Net assets attributable to holders of participating redeemable shares at the date of incorporation</b>		-
Proceeds from issuance of participating redeemable shares	11	25,079,127
Payments on redemption of participating redeemable shares	11	(1,474,374)
Increase in net assets attributable to holders of participating redeemable shares from operations		186,267
<b>Net assets attributable to holders of participating redeemable shares at the end of the period</b>	12	<u><u>23,791,020</u></u>

The notes 1 to 17 on pages 15 to 25 form part of these financial statements.

# Engelberg Global Fund IC Limited

## Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020

### Notes to the Financial Statements

#### 1. General Information

Engelberg Global Fund IC Limited (the "Incorporated Cell" or "Cell"), with company number 66191, is a Guernsey registered, Limited Liability Incorporated Cell of the Momentum Mutual Fund ICC Limited (the "Company"). The Cell was incorporated on 19 March 2019.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager"), with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager"), and Engelberg (Pty) Ltd acting as the Sub-Investment Manager.

The Cell is designed to offer a balance between capital preservation and capital growth over the full investment cycle. The diversified portfolio invests into a wide range of asset classes including cash, fixed income, high yield, equities and property. The Cell is ideally suited to investors with a medium risk tolerance and an investment horizon of 3 years or longer.

The investment objective is achieved through a diversified global portfolio that invests across a broad range of asset classes and currencies in varying proportions over time. These classes include international equities, fixed income, property, infrastructure, money market instruments and commodities. The Cell may invest in transferable securities, which are classes of investments that are negotiable on a capital market such as (but not limited to) shares in companies or bond investments. The Cell may also invest in other collective investment funds (including exchange traded funds) that invest in these asset classes, as well as mixed asset funds.

The Financial Statements were authorised for issue by the Board of Directors on 18 December 2020.

#### 2. Summary of significant accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

##### 2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards (IFRS). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The COVID-19 pandemic and the resultant uncertain economic environment and financial market volatility caused by it has created uncertainty in the operating environment of the Cell. All service providers have continued to operate effectively throughout the relevant COVID-19 local government restrictions. No concerns regarding liquidity, valuations or COVID-19 service provider issues have been identified that cause the Board to have any concern regarding the ongoing operation of the Cell or that require any changes to the Financial Statements of the Cell.

Notwithstanding the challenges arising from the impact of the COVID-19 virus, the Cell continues to operate, administer and price the Funds in accordance with regulatory requirements and in accordance with relevant accounting standards. Cell will continue to monitor fund liquidity and market volatility to ensure Funds are managed in the best interests of shareholders.

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions.

After careful consideration the Board are satisfied that it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of these Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

##### 2.2 Adoption of new and revised standards

*Standards, amendments and interpretations effective during the period*

The following accounting standards, amendments and interpretations became effective for the first time this period:

- (a) IFRS 16 Leases (effective date – 1 January 2019)
- (b) Definition of Material (Amendments to IAS 1 and IAS 8) (effective date – 1 January 2020)
- (c) Prepayment Features with Negative Compensation (Amendments to IFRS 9) (effective date – 1 January 2019)
- (d) Interest Rate Benchmark Reform (Amendments to IFRS 9, IAS 39 and IFRS 7) (effective date – 1 January 2020)

###### *(a) IFRS 16 Leases*

IFRS 16 introduces a single lessee accounting model and requires a lessee to recognise assets and liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value. A lessee is required to recognise a right-of-use asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. A lessee measures right-of-use assets similarly to other non-financial assets (such as property, plant and equipment) and lease liabilities similarly to other financial liabilities. As a consequence, a lessee recognises depreciation of the right-of-use asset and interest on the lease liability, and also classifies cash repayments of the lease liability into a principal portion and an interest portion and presents them in the statement of cash flows.

IFRS 16 contains expanded disclosure requirements for lessees.

The adoption of IFRS 16 had no material impact on the net assets attributable to holders of ordinary redeemable shares of the Incorporated Cell as the Cell is not party to any lease arrangements.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**2. Summary of significant accounting policies (continued)**

**2.2 Adoption of new and revised standards (continued)**

*(b) (Amendments to IAS 1 and IAS 8) Definition of Material*

The amendments in Definition of Material (Amendments to IAS 1 and IAS 8) clarify the definition of 'material' and align the definition used in the Conceptual Framework and the standards.

Information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity.

The adoption of above amendments to IAS1 and IAS8 had no material impact on the net assets attributable to holders of ordinary redeemable shares of the Incorporated Cell.

*(c) (Amendments to IFRS 9) Prepayment Features with Negative Compensation*

The IASB published Prepayment Features with Negative Compensation (Amendments to IFRS 9) to address the concerns about how IFRS 9 'Financial Instruments' classifies particular prepayable financial assets.

The amendments address changes regarding symmetric prepayment options and clarification regarding the modification of financial liabilities.

*Changes regarding symmetric prepayment options*

Management assessed the above and concluded the amendments have no effect on the Cell's Financial Statements as the Cell does not have any prepayable financial assets or interest-bearing financial liabilities that may require measurement modification.

*(d) (Amendments to IFRS 9, IAS 39 and IFRS 7) Interest Rate Benchmark Reform - effective 1 January 2020*

The amendments to IFRS 9, IAS 39 and IFRS 7 amend requirements for hedge accounting to support the provision of useful financial information during the period of uncertainty caused by the phasing out of interest-rate benchmarks such as interbank offered rates (IBORs) on hedge accounting.

- The amendments modify some specific hedge accounting requirements to provide relief from potential effects of the uncertainty caused by the IBOR reform.

- In addition, the amendments require companies to provide additional information to investors about their hedging relationships which are directly affected by these uncertainties.

The Board anticipates that the adoption of this standard, which will be adopted for the year ending 30 June 2021, will not have a material impact on the financial statements of the Incorporated Cell.

*Standards, amendments and interpretations that are not yet effective*

The following new standards, amendments and interpretations are not yet effective but will be applied, where relevant. Where EU effective date differs from the IASB effective date, these are explained below:

*IFRS 17 – Insurance Contracts (effective date – 1 January 2023)*

The Board anticipates that the adoption of this standard, which will be adopted for the year ending 30 June 2022, will not have a material impact on the financial statements of the Cell, on the basis that the Cell has not entered into any insurance contracts.

**2.3 Foreign currency translation**

**(a) Functional and presentation currency**

The currency in which the financial information is shown in the financial statements of the Incorporated Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Incorporated Cell, and in doing, so have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed and liquidity is managed. The Directors are of the opinion that the currency selected best represent the functional currency.

**(b) Transactions and balances**

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.

**2.4 Financial assets and financial liabilities at fair value through profit or loss**

**(a) Classification**

The Incorporated Cell classifies its investments in Collective Investment Schemes, equities, and related derivatives as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

**(b) Recognition/derecognition**

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**2. Summary of significant accounting policies (continued)**

**2.4 Financial assets and financial liabilities at fair value through profit or loss (continued)**

(c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

(d) Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Incorporated Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by their Fund administrators.

**2.5 Offsetting financial instruments**

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

**2.6 Forward currency contracts**

Forward foreign currency contracts are treated as derivative contracts and as such are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.

**2.7 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.

**2.8 Other financial instruments**

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

**2.9 Share capital**

The Incorporated Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

(a) Management shares

Management shares were issued to comply with Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 2 management shares.

(b) Participating redeemable shares

The Incorporated Cell's capital is represented by participating redeemable shares with no par value each carrying one vote, no matter which share class. Each share class carries identical rights, the only difference between the classes being either the management fee or the distribution partner fee which is charged to each class. These fees are disclosed in note 14.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

**2.10 Increase/(decrease) in net assets attributable to holders of participating redeemable shares from operations**

Income not distributed is included in Net Assets Attributable to Holders of Participating Redeemable Shares of the Incorporated Cell's financial statements.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**2. Summary of significant accounting policies (continued)**

**2.11 Capital risk management**

The fair value of the Cell's financial assets and financial liabilities approximate to their carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objective when managing capital is to safeguard its ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Incorporated Cell has no intention to borrow, other than to Fund short-term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

**2.12 Interest and dividend income**

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accruals basis.

**2.13 Expenses**

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

**2.14 Custodian bank charges**

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

**2.15 Taxation**

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,200 (2019:£1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.

**3. Financial risk management**

**3.1 Strategy in using financial instruments**

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the Cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance. The following policies and procedures to mitigate risk have been in place from 19 March 2019, the date of incorporation, to 30 June 2020.

The Cell's policy allows it to use derivative financial instruments to both moderate and create certain risk exposure. The fair value of derivative financial instruments as at 30 June 2020 is disclosed under note 9 of these financial statements.

**3.2 Market price risk**

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in collective investment schemes. Through its investment in traded securities and instruments, the Cell is subject to market movements in equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions are monitored regularly by the Investment Manager and are reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposures to varying product categories, hence concentration of risk is minimised. At the period end, the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

As at 30 June	2020	
	Fair Value	% of net assets
	<u>USD</u>	
Government Bonds	3,171,560	13.33
Collective Investment Schemes	20,406,608	85.78
	<u>23,578,168</u>	<u>99.11</u>

The Cell's market risk is affected by three main components: changes in actual market prices, interest rate and foreign currency exchange rates movements. Interest rate and foreign currency movements are covered in notes 3.3 and 3.5, respectively. If the market indices increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2020	
	Change in fair value	
	<u>USD</u>	
Government Bonds		317,156
Collective Investment Schemes		2,040,661
		<u>2,357,817</u>

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**3. Financial risk management (continued)**

**3.3 Interest rate risk**

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risk. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual repricing or maturity dates within one month.

<b>As at 30 June</b>	<b>2020</b>
	<b><u>USD</u></b>
Net financial assets on which no interest is paid	23,429,963
Net floating rate financial assets	<u>361,057</u>

Should interest rates have increased/decreased by 50 basis points with all other variables remaining constant, the increase/decrease in the net assets attributable to participating redeemable shareholders would amount to approximately:

<b>As at 30 June</b>	<b>2020</b>
	<b><u>USD</u></b>
Net floating rate financial assets	<u>1,805</u>

**3.4 Cash flow risk**

The Cell holds a limited amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

**3.5 Currency risk**

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments, denominated in currencies other than the US Dollar, the functional currency, and therefore it is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Where the Cell invests via Collective Investment Funds, the funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

<b>As at 30 June</b>	<b>2020</b>
	<b><u>USD</u></b>
GBP exposure	990,549
JPY exposure	(2,711)

In accordance with the Cell's policy, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk. Such contracts are used on a regular basis. The contracts which are outstanding at the period end are disclosed in note 9.

Should the Cell's functional currency have strengthened, or weakened, by 5% against other currencies to which it is exposed and all other variables, including the price of all investments, had held constant, the net asset attributable to participating redeemable shareholders would have increased, or decreased, as follows:

<b>As at 30 June</b>	<b>2020</b>
	<b><u>USD</u></b>
GBP exposure	49,527
JPY exposure	(136)

**3.6 Credit risk**

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by a Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2. No such redemption problems have been encountered.

All transactions in listed securities are settled/paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period, and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the Cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Cell's maximum exposure to credit risk is the carry value of the assets on the Statement of Financial Position.

## Engelberg Global Fund IC Limited

### Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020

#### Notes to the Financial Statements

#### 2. Financial risk management (continued)

##### 3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding its ability to process redemptions as normal.

The Cell has the ability to borrow to meet short term liquidity requirements, however, to date, the Cell has not entered into such arrangements.

The table below analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the Statement of Financial Position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

	2020		
	Less than 1 month	Between 1 and 12 months	Total
	<u>USD</u>	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss	23,578,168	-	23,578,168
Cash and cash equivalents	351,922	-	351,922
Interest receivable	9,135	-	9,135
Other receivables	3,987	-	3,987
Fair value of derivative financial instruments	(2,711)	-	(2,711)
Other payables	(37,681)	-	(37,681)
Due on redemption of redeemable preference shares	(111,800)	-	(111,800)
Net assets attributable to participating redeemable shares	(23,791,020)	-	(23,791,020)
<b>Net liquidity position</b>	<b>-</b>	<b>-</b>	<b>-</b>

Participating redeemable shares are redeemed on demand at the holder's option. However the Board of Directors does not envisage that the contractual maturity disclosed in the table on the previous page will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

##### 3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The overall strategy of the Cell remains unchanged.

The Cell has no externally imposed capital requirements.

##### 3.9 Fair value disclosure

In the opinion of the Directors there is no material difference between the net asset values of the underlying funds and fair values of the financial assets and liabilities of the Cell.

#### 4. Critical accounting estimates and judgements

The fair value of investments has been based on the listed market bid prices, or prices supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell does not hold any level 3 investments.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**5. Portfolio analysis**

The Cell's portfolio is organised by focusing on the type of security held and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types which are disclosed in note 3.2 and the following main geographical areas:

	<b>2020</b>
	<b>USD</b>
Channel Islands	952,587
Europe	19,454,020
United States of America	3,171,561
	<b><u>23,578,168</u></b>

The geographical segment for listed non-monetary financial assets is considered to be the place of primary listing and for non-listed financial assets where the underlying investment is domiciled.

**6. Financial assets at fair value through profit or loss**

	<b>2020</b>
	<b>USD</b>
<b>Financial assets at fair value through profit or loss:</b>	
Government Bonds	3,171,560
Collective Investment Schemes	20,406,608
<b>Total financial assets at fair value through profit or loss</b>	<b><u>23,578,168</u></b>
<b>Movement on financial assets at fair value through profit or loss</b>	
Fair value of financial assets at the date of incorporation	-
Purchases of financial assets	40,044,927
Sales of financial assets	(16,782,656)
Realised gains on sale of financial assets	(88,308)
Movement in unrealised gains on revaluation of financial assets	404,205
Fair value of financial assets at the end of the period	<b><u>23,578,168</u></b>
Comprising:	
Cost at the end of the period	23,173,963
Unrealised gains at the end of the period	404,205
	<b><u>23,578,168</u></b>

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 – inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**6. Financial assets at fair value through profit or loss (continued)**

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

The following tables present the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2020.

30 June 2020	Level 1 <u>USD</u>	Level 2 <u>USD</u>	Level 3 <u>USD</u>	Total <u>USD</u>
<b>Financial assets at fair value through profit or loss</b>				
Government Bonds	3,171,560	-	-	3,171,560
Collective Investment Schemes	20,406,608	-	-	20,406,608
	<u>23,578,168</u>	<u>-</u>	<u>-</u>	<u>23,578,168</u>

The Cell's cash and cash equivalents and short-term receivables and payables are recorded at carrying value which approximates fair value.

**7. Cash and cash equivalents**

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2020 <u>USD</u>
Cash at bank	351,922
	<u>351,922</u>

**8. Other receivables**

	2020 <u>USD</u>
Prepayments	3,987
Management shares receivable	100
Interest receivable	9,135
	<u>13,222</u>

**9. Fair value of derivative financial instruments**

Forward foreign exchange contracts designated as at fair value through profit or loss:

30 June 2020	Amount <u>CCY</u>	Maturity Date	Contracted rate	Closing rate	Contract value <u>USD</u>	Market value <u>USD</u>	Financial liabilities <u>USD</u>
Outstanding contract to buy JPY	95,000,000.00	15/07/2020	107.5539	107.8850	883,278	880,567	(2,711)
							<u>(2,711)</u>

In accordance with the Cell's investment objective the Cell may enter into forward foreign exchange contracts to hedge foreign currency movements they may be exposed to through their investment portfolios. As there is no assurance that these hedges will be effective in achieving the offsetting of changes in cash flows attributable to currency risk on these investments it is the policy of the Cell not to apply hedge accounting.

**10. Other payables**

	2020 <u>USD</u>
Audit fee payable	6,973
Custodian fee payable	899
Investment Management fee payable	6,562
Management fee payable	21,873
Sundry expenses payable	1,374
	<u>37,681</u>

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**11. Share capital**

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

<b>Management Shares in Issue</b>	<b>30.06.20</b>
	<u><b>USD</b></u>
Management shares	<u>100</u>

**For the period from 19.03.19  
(date of incorporation) to  
30.06.20**

**Participating Redeemable Shares in Issue - Class A**

Balance at the date of incorporation	-
Issue of participating redeemable shares	24,957,237
Redemption of participating redeemable shares	<u>(1,443,413)</u>
<b>Balance at the end of the period</b>	<u><b>23,513,824</b></u>

**For the period from 19.03.19  
(date of incorporation) to  
30.06.20**

**Participating Redeemable Share Capital Account - Class A**

	<u><b>USD</b></u>
Balance at the date of incorporation	-
Issue of participating redeemable shares	25,079,127
Redemption of participating redeemable shares	<u>(1,474,374)</u>
<b>Balance at the end of the period</b>	<u><b>23,604,753</b></u>

**12. Net asset value per participating redeemable share**

As at 30 June

	NAV per share	Net assets	
		attributable	Shares in issue
		2020	2020
	<u><b>USD</b></u>	<u><b>USD</b></u>	<u><b>USD</b></u>
Class A	1.01	23,791,020	23,513,824
		<u><b>23,791,020</b></u>	<u><b>23,513,824</b></u>

**13. Dividends payable to participating redeemable shareholders**

No dividends were paid during the period and the Board does not intend to pay any dividends. All available income will be reinvested.

**14. Related-party transactions**

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

**14.1 Management and Administration fee**

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

The Manager and the Administrator is entitled to receive the following Management and Administration fee, chargeable on a sliding scale, payable monthly in arrears, based on the current valuation and subject to a minimum annual fee of USD22,000 or currency equivalent of the Cell.

<b>Fee - % of NAV per annum</b>	<u><b>Cell NAV</b></u>
0.30%	Up to USD30m
0.25%	From USD30m to USD60m
0.20%	Over USD60m

Management and Administration fee charged during the period and accrued at period end:

	<b>For the period from 19.03.19 (date of incorporation) to 30.06.20</b>
	<u><b>USD</b></u>
Charged during the period	<u>45,764</u>
Accrued at period end	<u>6,562</u>

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**14. Related-party transactions (continued)**

**14.2 Investment Management fee**

The Manager has appointed an Investment Manager, Momentum Global Investment Management Limited, a UK registered company, to manage the investment portfolio of the Cell. The Investment Manager is entitled to receive the following Investment Management fee, chargeable on a sliding scale, payable monthly in arrears, based on the current valuation and subject to a minimum annual fee of USD50,000 or currency equivalent of the Cell. The minimum annual fee excludes the sub-investment management fee.

<u>Fee - % of NAV per annum</u>	<u>Cell NAV</u>
1.00%	Up to USD30m
0.975%	Over USD30m

Investment Management fee charged during the period and accrued at period end:

	<b>For the period from 19.03.19 (date of incorporation) to 30.06.20</b>
	<u>USD</u>
Charged during the period	161,040
Accrued at period end	21,873

**14.3 Sub-Investment Management Fee**

The Investment Manager has appointed Engelberg (Pty) Limited (the "Sub-Investment Manager"), a South African registered company to act as Sub-Investment Manager of the Cell.

Pursuant to the Sub-Investment Management Agreement, the Sub-Investment Manager is entitled to receive a fee equal to 0.75% of the NAV of the Cell per annum (the "Sub-Investment Management fee"), which will be paid out of the fee received by the Investment Manager. The Sub-Investment Management fee will accrue as at each valuation point, based on the current valuation and is payable monthly in arrears.

**14.4 Custodian fee**

Northern Trust (Guernsey) Limited was appointed to provide custodian services. The Custodian is entitled to receive a fee chargeable on a sliding scale in respect of all Share Classes, as per below subject to a minimum of USD8,000 per annum.

<u>Fee - % of NAV per annum</u>	<u>Cell NAV</u>
0.05%	Up to USD30m
0.04%	From USD30m to USD60m
0.03%	From USD60m to USD100m
0.02%	Over USD100m

Custodian fee charged during the period and accrued at period end:

	<b>2020</b>
	<u>USD</u>
Charged during the period	9,166
Accrued at period end	899

**14.5 Distribution Partner fee**

Pursuant to the Distribution Agreement dated 12 March 2019, the Directors and the Manager have appointed Engelberg (Pty) Limited as Distribution Partner. The Distribution Partner shall have the exclusive rights to promote and market the Cell and shall provide its services in the promotion, marketing and advertising of the Cell.

Pursuant to the Supplemental Cell Prospectus dated 24 July 2019, the Distribution Partner will not be paid a fee.

**14.6 Board of Directors' remuneration**

The Directors' fees shall not exceed USD20,000 or currency equivalent in any twelve month period. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the cellular assets of other cells of the Company or assets of the Company itself.

The Directors waived their right to a fee during the period.

**Engelberg Global Fund IC Limited**  
**Annual Report and Audited Financial Statements for the period from 19 March 2019 to 30 June 2020**

**Notes to the Financial Statements**

**15. Ultimate controlling party**

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.

**16. Reconciliation of published valuation to financial statements**

	<b>2020</b>
	<b><u>USD</u></b>
Net assets per financial statements	23,791,020
Adjustment:	
Adjustment in value of assets at financial assets at fair value through profit or loss	<u>119</u>
Net assets per published valuation	<u>23,791,139</u>
NAV per Class A per published valuation	<u>1.01</u>
NAV per Class A per financial statements	<u>1.01</u>

**17. Subsequent events**

These financial statements were approved for issuance by the Board on 18 December 2020. Subsequent events have been evaluated until this date. No significant subsequent events have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.